Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation.

José Esteban Costa Gil Juan Carlos Garnica CuéllarPaula Perez TernsAldo Ferreira-Hermosillo José Antonio Cetina CantoÁngel Alfonso Garduño PerezPedro Mendoza MartínezLucas RistaAlejandro Sosa-CaballeroEstefanía Vázquez-MendezLuis Fernando Tejado GallegosHungta ChenAgustina ElizaldeVirginia B Tomatis

Published in: Patient preference and adherence (2022)

Latin-American patients with T2D preferred medication with a profile resembling SGLT2i over one resembling DPP4i as a treatment option. A patient-centered approach may aid the healthcare team in decision-making for improved outcomes.

Keyphrases

healthcare
type diabetes
end stage renal disease
newly diagnosed
chronic kidney disease
cardiovascular disease
prognostic factors
skeletal muscle
patient reported outcomes
social media
drug induced